JP7820821B2 - アルツハイマー病の治療のための化合物及び方法 - Google Patents

アルツハイマー病の治療のための化合物及び方法

Info

Publication number
JP7820821B2
JP7820821B2 JP2022541987A JP2022541987A JP7820821B2 JP 7820821 B2 JP7820821 B2 JP 7820821B2 JP 2022541987 A JP2022541987 A JP 2022541987A JP 2022541987 A JP2022541987 A JP 2022541987A JP 7820821 B2 JP7820821 B2 JP 7820821B2
Authority
JP
Japan
Prior art keywords
brichos
amino acid
bri2
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022541987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509187A (ja
JP2023509187A5 (https=
Inventor
ヨハンソン、ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AlphaBeta AB
Original Assignee
AlphaBeta AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AlphaBeta AB filed Critical AlphaBeta AB
Publication of JP2023509187A publication Critical patent/JP2023509187A/ja
Publication of JP2023509187A5 publication Critical patent/JP2023509187A5/ja
Application granted granted Critical
Publication of JP7820821B2 publication Critical patent/JP7820821B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022541987A 2020-01-08 2021-01-07 アルツハイマー病の治療のための化合物及び方法 Active JP7820821B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20150738 2020-01-08
EP20150738.1 2020-01-08
PCT/EP2021/050168 WO2021140140A1 (en) 2020-01-08 2021-01-07 Compound and method for treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2023509187A JP2023509187A (ja) 2023-03-07
JP2023509187A5 JP2023509187A5 (https=) 2024-01-30
JP7820821B2 true JP7820821B2 (ja) 2026-02-26

Family

ID=69156193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541987A Active JP7820821B2 (ja) 2020-01-08 2021-01-07 アルツハイマー病の治療のための化合物及び方法

Country Status (5)

Country Link
US (1) US20230002458A1 (https=)
EP (1) EP4087860B1 (https=)
JP (1) JP7820821B2 (https=)
CN (1) CN115943153A (https=)
WO (1) WO2021140140A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079221A1 (en) 2022-10-12 2024-04-18 Alphabeta Ab The bri2 brichos domain for delivery of proteins into cns neurons
WO2025078660A1 (en) 2023-10-11 2025-04-17 Alphabeta Ab The bri2 brichos domain for treatment of parkinson´s disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533240A (ja) 2010-06-24 2013-08-22 アルファベータ・エービー アルツハイマー病および家族性認知症の治療のための化合物および方法
JP2014516407A (ja) 2011-04-05 2014-07-10 アルファベータ・エービー 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058353A1 (en) * 1998-12-10 2000-10-05 Shanghai Second Medical University Npcahh01: human transmembrane protein e3-16 gene
WO2006138355A2 (en) * 2005-06-14 2006-12-28 Albert Einstein College Of Medicine Of Yeshiva University Effect of bri proteins on abeta production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533240A (ja) 2010-06-24 2013-08-22 アルファベータ・エービー アルツハイマー病および家族性認知症の治療のための化合物および方法
JP2014516407A (ja) 2011-04-05 2014-07-10 アルファベータ・エービー 治療の方法においておよび化合物のスクリーニングのために有用なアミロドーシスターゲット

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Sanchez-Pulido L et. al.，BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer，Trends Biochem Sci，2002年，27(7)，pp. 329-32
Willander H et. al.，BRICHOS domains efficiently delay fibrillation of amyloid β-peptide，J Biol Chem，2012年，287(37)，pp. 31608-17

Also Published As

Publication number Publication date
EP4087860C0 (en) 2023-11-22
CN115943153A (zh) 2023-04-07
EP4087860B1 (en) 2023-11-22
WO2021140140A1 (en) 2021-07-15
JP2023509187A (ja) 2023-03-07
US20230002458A1 (en) 2023-01-05
EP4087860A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
Souchet et al. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice
US9862761B2 (en) Composition and method for preventing or treating a tauopathy
Liu et al. Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology
CN101611152A (zh) 用于调控set的方法及其用途
Cai et al. Chronic cerebral hypoperfusion promotes amyloid-beta pathogenesis via activating β/γ-secretases
KR20200095485A (ko) 보체 활성의 조절인자
JP7820821B2 (ja) アルツハイマー病の治療のための化合物及び方法
CN104321337A (zh) 肽及其用途
Parra Bravo et al. Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury
Lin et al. Ozone inhibits APP/Aβ production and improves cognition in an APP/PS1 transgenic mouse model
US20250017884A1 (en) Compositions and methods for treating alzheimer's disease
Liu et al. Role of mitochondrial quality control in neurodegenerative disease progression
Yang et al. A peptide binding to the β-site of APP improves spatial memory and attenuates Aβ burden in Alzheimer’s disease transgenic mice
GB2571978A (en) Uses, compositions and methods
Zhang et al. Protective effect of S14G-humanin against beta-amyloid induced LTP inhibition in mouse hippocampal slices
Liu et al. Biological effects and mechanism of β-amyloid aggregation inhibition by penetrable recombinant human HspB5-ACD structural domain protein
Morrissey et al. The tripeptide RER mimics secreted amyloid precursor protein-alpha in upregulating LTP
KR20180133865A (ko) 혈전성 혈소판감소성 자반 치료 약물 제조에 사용하는 항혈소판 트롬볼리신의 응용
Lee et al. HDAC6 regulates BACE1 stability and NLRP3 inflammasome activation in Alzheimer’s disease
Habib Therapeutic Modulation of Alzheimer's Disease with Biological (HUCBS) and Pharmacological (LISPRO) Approaches
Hintermayer The Role of the Tau N-Terminal Phosphatase-Activating Domain and Phosphorylation at Thr175 in the Formation of Tau Cytoplasmic Inclusions
Watson Dissecting the role of MAP3Ks TAK1 and ASK1 in IgE-FcεRI mediated mast cell exocytosis
Borbély Development of Non-Transgenic Animal Models of Alzheimer’s Disease and Investigation of Drug Candidates for its Treatment
Ospina Small Heat Shock Protein 22 Preserves Neuronal Function in a Murine Model of Tauopathy
Su et al. TNMD BRICHOS domain attenuates tau pathology and memory deficits in a mouse model of tauopathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260205

R150 Certificate of patent or registration of utility model

Ref document number: 7820821

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150